Survodutide, a dual GLP-1 and glucagon receptor agonist, produced around 19 percent weight loss in phase 2 trials
A distinct visual change occurred during the process, with the reaction mixture transitioning from yellow to a noticeable red color, signaling the reduction of selenite and the formation of SeNPs
What the trial is measuring: The primary outcome is a change in body weight
However, off-label prescribing carries additional responsibilities, including thorough informed consent discussions about the lack of specific evidence for the condition being treated
Many people continued other forms of treatment after stopping GLP-1 drugs, which may help explain why large weight regain was not commonly observed
A prescription should be the beginning, not the end, of your care